Blood Screening Market by Product & Service, Technology, End-User

List of Tables

[193 Pages Report] The Blood Screening Market size was estimated at USD 4.90 billion in 2023 and expected to reach USD 5.31 billion in 2024, at a CAGR 8.74% to reach USD 8.82 billion by 2030.

Blood screening is a crucial aspect of healthcare that involves analyzing and testing blood samples to detect potential health issues, infections, or disorders. It serves as a vital diagnostic and monitoring tool, ensuring the safety of blood transfusions organ transplants, and tracking the prevalence of various diseases in a population. The increasing number of blood donations/transfusions worldwide, the rising prevalence of infectious disorders, and technological advancements in molecular diagnostics increase the need for blood screening. However, high upfront costs associated with implementing new technologies and a lack of awareness about available tools in underdeveloped regions significantly impede the adoption of blood screening. Additionally, manufacturers focusing on next-generation sequencing (NGS), CRISPR gene-editing techniques, and artificial intelligence (AI) diagnostics applications offer promising avenues for improving testing accuracy, speed, and cost-efficiency. Manufacturers identify novel biomarkers for various diseases and enhance early detection capabilities, leading to better patient outcomes and increased demand for advanced blood screening tests.

KEY MARKET STATISTICS
Base Year [2023]	USD 4.90 billion
Estimated Year [2024]	USD 5.31 billion
Forecast Year [2030]	USD 8.82 billion
CAGR (%)	8.74%

Product: Rising adoption of instruments and consumables for conducting accurate tests

The blood screening process relies heavily on sophisticated instruments capable of conducting rapid and accurate tests for various pathogens. These instruments help detect infectious agents and enable healthcare professionals to quantify their presence in a given sample. Consumables facilitate accurate and efficient testing while minimizing risks associated with cross-contamination between samples. Consumables in blood screening include micropipette tips, microplates, filter tips & tubes, cuvettes & vials, syringe filters, and other disposable equipment. Blood screening also heavily depends on various reagents that react with specific pathogens or compounds within a sample to produce measurable signals indicating the presence of infectious agents.

Technology: Development of enzyme-linked immunosorbent assay and mass spectrometry technology

Nucleic acid testing (NAT) is a sensitive molecular technique for detecting viral nucleic acids at very low levels in blood samples. Enzyme-linked immunosorbent assay (ELISA) is an immunoassay technique utilized to screen blood samples for antibodies and antigens related to infectious diseases such as HIV, Hepatitis B and C, and Syphilis. Polymerase chain reaction (PCR) is another widely-used molecular diagnostic method that enables rapid detection of specific nucleic acid sequences within a given sample. Mass spectrometry (MS) is an analytical process for identifying and characterizing molecules based on their mass-to-charge ratio (m/z). Flow cytometry is a cell-based technology that allows for rapid analysis of cellular properties by measuring the scattering of light as cells flow through a laser beam.

Application: Significant applications of infectious disease and cancer screening to prevent the spread of infections

Blood screening for infectious diseases is critical for supporting public health and preventing the spread of infections. Blood typing is an essential blood screening process to determine an individual's blood group (ABO system) and Rh factor (positive or negative). Early detection through cancer-specific blood screening has become increasingly relevant with advancements in diagnostic technology. Genetic blood tests analyze DNA to identify inherited disorders, assess the risk of developing specific diseases, and guide personalized treatment plans.

End-User: Increasing use of blood screening in hospitals and laboratories

Hospitals & clinics serve as primary contact points for patients needing blood tests as part of their medical treatment or diagnosis. They collect and process samples on-site or send them to external laboratories for further analysis. Diagnostic laboratories specialize in analyzing biological samples through an array of testing methods such as nucleic acid amplification tests (NAAT), enzyme-linked immunosorbent assay (ELISA), or chemiluminescent immunoassay (CIA). For transfusion, blood banks collect, store, process, test, and distribute blood products, such as whole blood, plasma, platelets, red cells, and white cells. Research institutions, including universities, government agencies, and private organizations, contribute to the development of novel technologies and methodologies for blood screening.

Regional Insights

In the Americas, the demand for blood screening tests is increasing due to their advanced healthcare systems, high-quality research institutions, and funding for innovation. The U.S. Food and Drug Administration (FDA) significantly approves new blood screening technologies to ensure safety and efficacy. In Asia Pacific, rapid economic growth, expanding healthcare infrastructure, and a large patient population are prone to infectious diseases due to high population density. China has recently implemented stringent blood safety regulations following past transfusion-related scandals, leading to increased demand for advanced screening technologies. The European Union (EU) countries have a highly developed healthcare system with strict blood transfusion services regulations. Investments in R&D activities focused on novel diagnostic technologies contribute to Europe's robust blood screening industry. The Middle East & Africa region showcases a diverse landscape with varying levels of healthcare infrastructure development. Many African countries face challenges relating to inadequate infrastructure and resources for ensuring safe transfusions, posing health risks to recipients.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Blood Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Blood Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Blood Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alfa Scientific Designs, Inc., Becton, Dickinson And Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMerieux SA, Danaher Corporation, DiaSorin S.p.A., Environmental & Scientific Instruments Co., F. Hoffmann-La Roche AG, GE HealthCare Technologies, Inc., GFE, Grifols, S.A., Immucor, Inc., Laboratory Corporation of America Holdings, Lifeloc Technologies, Inc, Omega Laboratories, Inc., OraSure Technologies, Inc., Ortho Clinical Diagnostics, Inc., PerkinElmer, Inc., PixCell Medical Technologies Ltd., Premier Biotech, Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech Plc.

Market Segmentation & Coverage

This research report categorizes the Blood Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product & Service
- Instruments
- Outright Purchase
- Reagents & Kits
  - ELISA Reagents & Kits
    - Conjugates
    - Controls
    - Immunosorbents
    - Sample Diluents & Wash Solutions
    - Substrates

NAT Reagents & Kits
- Buffers, Nucleotides, & Solutions
- Enzymes & Polymerases
- Labeling & Detection Reagents
- Probes & Primers
- Standards & Controls

Technology
- ELISA
  - Chemiluminescent Immunoassay
  - Colorimetric Immunoassay
  - Fluorescent immunoassay

NAT
- Real-Time Polymerase Chain Reaction
- Transcription-Mediated Amplification

NGS
Rapid Tests
Western Blot Assays

End-User
- Blood Banks
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Blood Screening Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Blood Screening Market?

3. What are the technology trends and regulatory frameworks in the Blood Screening Market?

4. What is the market share of the leading vendors in the Blood Screening Market?

5. Which modes and strategic moves are suitable for entering the Blood Screening Market?

Product Code: MRR-374DB5A06BE3

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing demand for donated blood and rising number of blood donations
  - 5.1.1.2. Rising prevalence of infectious diseases and the emergence of newer pathogens
  - 5.1.1.3. Increase in affordability and adoption of nucleic acid test for blood screening
- 5.1.2. Restraints
  - 5.1.2.1. High price for blood screening diagnostics
- 5.1.3. Opportunities
  - 5.1.3.1. Technological Advancements in blood screening devices
  - 5.1.3.2. Improved POC diagnostics for blood screening
- 5.1.4. Challenges
  - 5.1.4.1. Lack of legislation, regulations, and policies on blood screening
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising adoption of instruments and consumables for conducting accurate tests
- 5.2.2. Technology: Development of enzyme-linked immunosorbent assay and mass spectrometry technology
- 5.2.3. Application: Significant applications of infectious disease and cancer screening to prevent the spread of infections
- 5.2.4. End-User: Increasing use of blood screening in hospitals and laboratories
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Blood Screening Market, by Product & Service

6.1. Introduction
6.2. Instruments
6.3. Outright Purchase
6.4. Reagents & Kits

7. Blood Screening Market, by Technology

7.1. Introduction
7.2. ELISA
7.3. NAT
7.4. NGS
7.5. Rapid Tests
7.6. Western Blot Assays

8. Blood Screening Market, by End-User

8.1. Introduction
8.2. Blood Banks
8.3. Hospitals

9. Americas Blood Screening Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Blood Screening Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Blood Screening Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Harbinger Health Raises $140M to Study Blood-Based Cancer Screening Test
- 12.3.2. Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch Prostate Screening Blood Test to Men With Prostate Cancer Risk
- 12.3.3. Walgreens and Freenome to Advance Blood-Based Test Trials For Cancer
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio